Press Releases

    • JUN 29 2015

    Cell Cycle Study Finds that ONC201 Is Effective In Pediatric NHL

    Hummelstown, PA (June 29, 2015) – Oncoceutics, Inc. announced publication of novel findings in the journal Cell Cycle that demonstrate ONC201 is an effective anti-cancer agent against pediatric non-Hodgkin’s lymphoma (NHL) as a monoagent and in combination with other chemotherapeutic agents. The anti-cancer activity of ONC201 has been demonstrated in several preclinical models, including refractory

    • MAY 26 2015

    First-­in-­Man ONC201 Trial to be Presented at 2015 ASCO Meeting

    Hummelstown, PA (May 26, 2015) – Oncoceutics, Inc. announced that details of a clinical phase I study in advanced solid tumors of its lead compound, ONC201, will be presented at the annual conference of the American Society of Clinical Oncology (ASCO) in Chicago on Saturday, May 30. The clinical study is being conducted at Rutgers

    • MAY 05 2015

    Proprietary Discovery Method for First-in-class ONC201 Published

    Hummelstown, PA (May 05, 2015) – Oncoceutics, Inc. announced publication of a research article in the journal Molecular Cancer, which describes the discovery of ONC201 as a selective lead compound with a novel chemical structure and novel mechanism of action that warranted clinical testing.In an attempt to identify inducers of tumor cell death that spare

    • MAR 31 2015

    ONC201 Featured in Seven Abstracts at 2015 AACR Meeting

    Hummelstown, PA (March 31, 2015) – Oncoceutics, Inc., a drug discovery and development company targeting the most potent suppressor pathways in human cancer, along with its collaborators, has been selected to present at the 106th Annual Meeting of the American Association for Cancer Research (AACR), to be held in Philadelphia. The seven abstracts selected for